glycolipid/inflammation

FIELD OF THE PRESENT INVENTION The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in

FIELD OF THE INVENTION The present invention provides a novel series of sulfated .alpha.-glycolipid compounds, pharmaceutically acceptable salts and pharmaceutical compositions thereof as inhibitors of selectin-mediated cellular adhesion which are useful in the treatment or prevention of

CROSS-REFERENCE TO RELATED APPLICATION This nonprovisional application claims the benefit of copending provisional application, U.S. Ser. No. 60/006,468, filed Nov. 13, 1995. FIELD OF THE INVENTION The present invention provides a novel series of malonate derivatives of glycolipid compounds,

FIELD OF THE INVENTION The present invention provides a novel series of sulfated .beta.-glycolipid compounds, pharmaceutically acceptable salts and pharmaceutical compositions thereof as inhibitors of selectin-mediated cellular adhesion which are useful in the treatment or prevention of inflammatory

FIELD OF THE INVENTION The present invention relates to methods and glycolipid compounds for the treatment of inflammatory disease, such as asthma and autoimmune diseases. BACKGROUND OF THE INVENTION Bronchial asthma, a complex and heterogeneous trait, is a major public health problem, affecting

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention provides methods of treatment and prevention of selectin-dependent acute lung injury and diseases which result from selectin-dependent acute lung injury by administration of a sulfatide. The present invention also provides

CROSS-REFERENCE TO RELATED U.S. APPLICATIONS This application claims priority to Israeli Application No. 1,721,17, filed Nov. 24, 2005, which is incorporated by reference in its entirety herein. FIELD OF THE INVENTION The invention relates to the use of .beta.-glycolipids as immunomodulators. More

FIELD OF THE INVENTION The invention relates to the use of synthetic derivatives of .beta.-glycolipids as immunomodulators. More particularly, the invention relates to the use of synthetic derivatives of .beta.-glycolipids, preferably, the compounds of any one of Formula I, II, III and IV or any

CROSS REFERENCE TO RELATED APPLICATIONS The present application is the US national stage of International Application PCT/EP2009/059565 filed on Jul. 24, 2009 which, in turn, claims priority to Italian Patent Application MI 2008A001370 filed on Jul. 25, 2008. FIELD OF THE INVENTION The present

FIELD OF THE INVENTION The invention relates to pharmaceutical compositions comprising the .alpha.-Gal glycolipid (9Z,9'Z)-(2R)-3-(((2-(6-((3-(((2R,3R,4R,5S,6R)-3-acetamido-5-(((2S,3R,4S,- 5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(((2R,3R,4S,5R,6R)-3,4,5-trihydro-

INCORPORATION BY REFERENCE OF SEQUENCE LISTING The Sequence Listing in an ASCII text file, named as 28002_5594_04_SequenceListing.txt of 7 KB, created on Feb. 24, 2014, and submitted to the United States Patent and Trademark Office via EFS-Web, is incorporated herein by reference. FIELD OF THE

BACKGROUND OF THE INVENTION Cells recruited to a site of inflammation represent pivotal components of the human inflammatory response. These cells include a large array of immune cells which may exert a beneficial effect due to their combined ability to combat infection and promote the restoration

FIELD OF INVENTION The present invention is related to the field of cancer treatment. In one embodiment, the invention contemplates administering compounds to tumor lesions that induce local expression of .alpha.-gal epitopes within the tumor. In one embodiment, the administration induces regression

The present invention relates to novel piperidine derivatives useful as inhibitors of glucosylceramide synthase (GCS; UDP-glucose:ceramide glucosyltransferase, UDP-glucose:N-acylsphingosine D-glucosyltransferase, EC 2.4.1.80), methods for their preparation and their use in medicine, specifically in

The present invention relates to a novel piperidine derivative useful as an inhibitor of glucosylceramide synthase (GCS; UDP-glucose:ceramide glucosyltransferase, UDP-glucose:N-acylsphingosine D-glucosyltransferase, EC 2.4.1.80), methods for its preparation and its use in medicine, specifically in